Aegera Therapeutics, Pharmion, Hybridon, New York Academy of Sciences, and CytRx | GenomeWeb

Aegera Closes $15 Million Round of Financing

Aegera Therapeutics said this week that it has closed a $15 million Series C round of financing.

The financing, said the company, was led by VenGrowth Advanced Life Sciences Fund and included new and existing investors. Proceeds of the financing will be used to support the clinical development of Aegera’s lead product candidates, including a phase I antisense cancer drug.

FDA Grants Pharmion’s Demethylating MDS Drug Priority Review

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.